Marburg Virus Outbreak: Rwanda Reports 20 Cases

Updated Sep 30, 2024 | 09:08 AM IST

SummaryThe latest outbreak in Africa is in Rwanda, it is the Marburg virus which have so far killed 6 people. Read on to know more about it.
Marburg Virus

Credits: Canva

After mpox outbreak, Africa is under the threat of yet another virus outbreak, this is the Marburg virus outbreak in Rwanda. So far, six people have died from the outbreak, confirmed the health minister. Most victims were the healthcare workers in the hospital's intensive care unit. As per reports, 20 cases have been identified since the outbreak was confirmed on Friday.

What Is Marbug Virus?

With the fatality rate of 8% it is the same virus family as Ebola. The main carrier is from fruit bats which spreads to humans then through the contact of bodily fluids of infected individuals, it spreads to others.

Common Signs And Symptoms

The common signs and symptoms of the Marburg virus include fever, pain, diarrhoea, vomiting and in the case of extreme blood loss, death too can happen.

So far, there is no specific treatment or vaccine for the virus. However, treatments like drugs and immune therapy are being developed as per the World Health Organisation (WHO).

Call Of Action

Rwanda says that it has intensified its contact tracing, surveillance and testing to contain the spread. It has also tracked about 300 people who had come into contact with individuals affected by the Marburg virus.

The health minister has urged people to stay vigilant and avoid any physical contact and to wash their hands with clean water, soap or sanitiser and report any suspected case.

As of now, most of the cases have spread to the capital in Kigali. In light of this, the US Embassy in the city has advised its employees to work remotely for the next week.

This is the first time Rwanda has confirmed for Marburg cases, before this, in 2023, Tanzania confirmed the outbreak, whereas three people had died of this in Uganda in 2017.

History Of Marburg

As per WHO, this virus kills half of the people it infects. In the previous outbreaks, it has killed between 24% to 88% of the patients.

The virus was first detected in 1976 after 31 people were infected, out of which 7 died in simultaneous outbreak in Marburg and Frankfurt in Germany, and Belgrade in Serbia.

The source was traced to African green monkeys who were imported from Uganda. However, other animals too are linked to the virus spread, including bats.

In the past, the virus outbreaks have happened in countries like Equatorial Guinea, Ghana, the Democratic Republic of the Congo, Kenya, South Africa, Uganda, and Zimbabwe. In 2005, this virus killed 300 people in Angola.

However, for the rest of the world, only two people have died from the virus in the rest of the world, with one of them being in Europe, and the other in the US. These both have been on expeditions to caves in Uganda.

End of Article

Ozempic Will Go Generic, Weight-loss Drug Cost Could Lower By 90%

Updated Mar 21, 2026 | 10:07 AM IST

SummaryGeneric versions of semaglutide weight loss drugs like Ozempic and Wegovy are expected to launch in several countries including India, potentially reducing prices by up to 90 percent and expanding access for millions with obesity and diabetes.
Ozempic Will Go Generic, Weight-loss Drug Cost Could Lower By 90%

Credits: Canva

Semaglutide: Weight loss drug like Ozempic and Wegovy are going to go generic in countries. This means the drug, but in cheaper rates, will be available to the 40 per cent of the world's population.

Novo Nordisk that until now had the monopoly over the drug will lose patent protection in several of the world's most populous countries. Health and Me had also previously reported that the first generic version is expected to arrive in India by this weekend. Soon after, generic drugs will also become available in China, Canada, Brazil, Turkey, and South Africa.

“The availability of these drugs, which have been restricted to high-income countries to very wealthy people, will now be democratized by the generics,” said Leena Menghaney, an activist in New Delhi focused on treatment access. The new markets will open up a huge customer base for the generic weight loss drugs. In India and China, there are more than 800 million obese adults or overweight, and more than 300 million adults have diabetes.

Drugs Could Be Cheaper By 90%

The generic drugs are expected to hit the shelves of Indian markets by 21 March, and costs are expected to be lower by 90 per cent. Drug makers like Nacto Pharma and Eris Lifesciences announced to roll out the weight loss jabs over 50 per cent cheaper than the innovator's price in April. They have also introduced vials for Rs 1,300 per month, which is about 90 per cent cheaper than Ozempic.

Dr Reddy's Laboratories is also gearing up to launch its generic semglutide injection in the country in March under the brand name Obeda. Other companies like Sun Pharma and Zydus Lifesciences too are entering the rat race of launching multiple generic versions to make the treatment more affordable for patients with obesity and weight-related health risks.

Until the patent is expired, the semaglutide therapies are owned by the original company. In India, semaglutide injections like Ozempic and Wegovy are soled at a high cost that has limited accessibility to many patients.

Industry analysts, as reported by NDTV, expect that one generic semaglutide enters the market from March 21, 2026, prices could be cut roughly by 50 per cent as compared to the prices it started with. This means Wegovy which was previously sold for around Rs. 10,000 per month could fall somewhere between Rs 3,500 to Rs. 4,000 per month for starter doses.

Dr Reddy's Laboratories have positioned their generic brands competitively, and could potentially offer discounts of up to 50 to 60 per cent in early competition.

How Does Semaglutide Work?

Semaglutide works as a GLP-1 receptor agonist that mimics the GLP-1 hormone to regulate appetite and blood sugar. It slows gastric emptying and makes you feel fuller longer. It also signals the brain to reduce hunger and cravings, and triggers the pancreas to release insulin when blood sugar is high.

They work by increasing insulin release in a glucose-dependent manner, decreasing the liver's production of glucagon, and slowing down the emptying of the stomach, which helps lower blood sugar levels after a meal. They also act on the brain to suppress appetite and increase feelings of fullness, leading to reduced calorie intake.

In people with type 2 diabetes, notes Harvard Health, the body's cells are resistant to the effects of insulin and body does not produce enough insulin, or both. This is when GLP-1 agonists stimulate pancreas to release insulin and suppress the release of another hormone called glucagon.

These drugs also act in the brain to reduce hunger and act on the stomach to delay emptying, so you feel full for a longer time. These effects can lead to weight loss, which can be an important part of managing diabetes.

End of Article

NATCO Pharma 1st To Launch Generic Semaglutide In India, Prices Start From Rs 1,290

Updated Mar 20, 2026 | 09:10 PM IST

SummaryNovo Nordisk is expected to lose the patent in 10 more countries, including Brazil, China, South Africa, Turkey, and Canada, by the end of 2026.
NATCO Pharma 1st To Launch Generic Semaglutide In India, Prices Start From Rs 1,290

With the patent on semaglutide expiring today in India, NATCO Pharma has become the first drugmaker to launch the generic version of the weight-loss drug in the country.

NATCO Pharma’s generic semaglutide injection prices start at INR 1,290 per month.

“NATCO is the first company to offer generic semaglutide in multi-dose vials with customized syringes… It is the most affordable GLP-1 currently in the Indian market as it is approximately 70 percent cheaper in cost than the pen device and 90 percent cheaper than the price of the innovator’s brand,” the Hyderabad-based company said, in a statement.

The company had received approval from the Central Drugs Standard Control Organization (CDSCO) in February 2026 to manufacture and market the drug, after a clinical comparison study.

Semaglutide works by targeting key areas of the brain involved in appetite regulation and food intake. It reduces hunger, improves satiety, and cuts down food cravings, eventually inducing weight loss.

It also improves insulin resistance and has a beneficial effect on the reduction of cardiometabolic events and risk factors.

NATCO's Semaglutide Drugs

NATCO's semaglutide drugs will be sold under brand names SEMANAT and SEMAFULL in multi-dose vial formats. It will be priced:

  • INR 1,290 per month for the 2 mg/1.5 ml and 4 mg/3 ml variants,
  • INR 1,750 for the 8 mg/3 ml dose.
In addition, NATCO is also expected to launch its pen device in April. It will be priced at

  • INR 4,000 for 2 mg/1.5ml,
  • INR 4,200 for 4 mg/3 ml,
  • INR 4,500 per month for 8 mg/3 ml.

In comparison, Novo Nordisk's Ozempic and Wegovy in pen devices cost INR 8,800 and INR 10,850, respectively, per month for the starting doses.

NATCO has also signed a distribution partnership with Eris Lifesciences to co-market its therapy in India.

Other Generic Versions

Separately, Eris has also announced its plans to launch a multi-dose vial under the brand name "Sundae". The company's generics will be at the same price for the type-2 diabetes indication.

Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Zydus Lifesciences are also expected to introduce their versions of semaglutide on Saturday.

Others in the pipeline include Alkem Laboratories, Torrent Pharmaceuticals, and MSN Laboratories.

With intense competition, analysts believe around 50 branded semaglutide generics will enter the Indian market within months, BBC reported.

Calling it a potential "magic-pill moment" for India, investment bank Jefferies predicted that the semaglutide market in the country could reach $1bn domestically.

Also read: CDSCO threatens action against pharma companies for promoting GLP-1 weight-loss drugs

End Of Novo Nordisk’s Patents

In January this year, Canada became the first country to lose patent protection for semaglutide. However, the country's health regulator hasn’t approved any generics so far.

Novo Nordisk is expected to lose the patent in 10 more countries, including Brazil, China, South Africa, Turkey, and Canada, by the end of 2026.

In view of losing patent, Novo Nordisk recently cut prices for Wegovy in India. The company also launched its blockbuster brand Ozempic in December.

End of Article

New AIIMS Study To Probe How PM2.5 Is Surging Lung Cancer Risk In India

Updated Mar 20, 2026 | 06:00 PM IST

SummaryData from the National Cancer Registry shows that lung cancer affects about 72,000 people and claims 66,000 lives every year in India. The new AIRCARE study will examine the connection between the PM 2.5 and the risk of lung cancer in the country.
New AIIMS Study To Probe How PM2.5 Is Surging Lung Cancer Risk In India

Credit: iStock

Once affecting people who smoked tobacco, lung cancer in India is today more common among people who never smoked. The major reason: exposure to poor air, almost year-round.

Although air pollution has emerged as an important risk for lung cancer, the evidence on this issue from India is limited. To explore more on this, the All India Institute of Medical Sciences, Delhi, today announced undertaking a major study.

The study, dubbed ‘AIRCARE (Air Pollution and Cancer Research Ecosystem): Center for Advanced Research on Environmental Health and Lung Cancer Risk’, will examine the connection between the fine particulate matter 2.5 (PM 2.5) and the risk of lung cancer in the country.

PM2.5 particles, with a diameter of 2.5 micrometers or less, are approximately 30 times smaller than a human hair. It is a significant yet often unseen threat to air quality.

“India is home to some of the most polluted cities in the world, and there is an urgent need to scientifically look at the effects of pollution on people’s health. Lung cancer is one of the most common cancers among males in India, and there is a high number of non-smoking lung cancers among females and young adults,” said Dr. Abhishek Shankar, Assistant Professor, Radiation Oncology at AIIMS, who will lead the study, while addressing the media.

“It is deeply concerning that lung cancer, once assumed to be a disease mostly associated with people who smoke tobacco, is now seeing a rapid increase in incidence amongst people who do not smoke,” he added.

The expert urged the "need to implement policy and management strategies to tackle this disease and mitigate further loss of life”.

The AIRCARE Study

It will be the first-of-its-kind scientific study in India to evaluate the effects of exposure to air pollution.

About 1,615 lung cancer cases with 1,615 controls from their family members will be added to the study.

The study will employ both a cohort and case-control design to track the effects of chronic PM 2.5 exposure on lung cancer incidence across various demographics and socio-economic groups.

It will also attempt to isolate an Indian population-specific genetic imprint.

Based on the findings, the researchers aim to develop a risk- based screening model that will include both clinical and molecular components specific to the Indian population and exposure levels.

It will also identify the susceptible population among the cohort who are more at risk of developing lung cancer.

Lung Cancer And Air Pollution Risks In India

Data from the National Cancer Registry shows that lung cancer affects about 72,000 people and claims 66,000 lives every year in India -- making it one of the leading causes of cancer mortality in the country.

From a smoker’s illness, lung cancer has now emerged as a major concern due to poor air quality. Several doctors across Delhi and Maharashtra have n noted a significant increase in pulmonary cancer due to air pollution.

A 2025 study at a government hospital in North India found that 52 percent of lung cancer cases were among non-smokers.

End of Article